Lazard Asset Management’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.13M Buy
28,830
+1,230
+4% +$47.5K ﹤0.01% 1141
2026
Q2
$1M Sell
27,600
-6,206
-18% -$196K ﹤0.01% 1228
2026
Q1
$947K Buy
33,806
+2,703
+9% +$88.6K ﹤0.01% 1193
2025
Q4
$1.16M Sell
31,103
-2,588
-8% -$85.1K ﹤0.01% 1108
2025
Q3
$929K Sell
33,691
-45,052
-57% -$1.55M ﹤0.01% 1165
2025
Q2
$2.49M Sell
78,743
-36,110
-31% -$1.16M ﹤0.01% 939
2025
Q1
$3.81M Buy
114,853
+105,629
+1,145% +$3.79M 0.01% 762
2024
Q4
$316K Buy
9,224
+2,541
+38% +$87.3K ﹤0.01% 1492
2024
Q3
$266K Sell
6,683
-6
-0.1% -$211 ﹤0.01% 1541
2024
Q2
$200K Buy
6,689
+2,147
+47% +$64.6K ﹤0.01% 1558
2024
Q1
$152K Buy
4,542
+2,251
+98% +$72.2K ﹤0.01% 1397
2023
Q4
$73K Buy
2,291
+109
+5% +$3.04K ﹤0.01% 1784
2023
Q3
$71K Buy
2,182
+427
+24% +$14.8K ﹤0.01% 1751
2023
Q2
$61K Buy
+1,755
New +$60.6K ﹤0.01% 1765
2022
Q3
– Sell
-1,566
Closed -$76K – 2425
2022
Q2
$76K Buy
+1,566
New +$70.5K ﹤0.01% 1619

Other funds holding HRMY

Lazard Asset Management's HRMY Position: Q3 2026 in Review

Lazard Asset Management increased its Harmony Biosciences (HRMY) stake by 4.5% in Q3 2026, buying an estimated $47.5K and bringing the position to 28,830 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1141.

Lazard Asset Management first reported a position in HRMY in Q2 2022 and has held it in 15 quarters since. The position peaked at $3.81M in Q1 2025. 358 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • Lazard Asset Management held 28,830 shares of Harmony Biosciences worth $1.13M as of Q3 2026.
  • Lazard Asset Management bought 1,230 Harmony Biosciences shares in Q3 2026, an estimated $47.5K.
  • Harmony Biosciences made up ﹤0.01% of Lazard Asset Management's portfolio in Q3 2026, its #1141 holding.
  • Lazard Asset Management first reported a position in Harmony Biosciences in Q2 2022 and has held it in 15 quarters since.
  • Lazard Asset Management's Harmony Biosciences position peaked at $3.81M in Q1 2025.
  • 358 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.